Skip to main content
Erschienen in: Hepatology International 5/2020

04.07.2020 | COVID-19 | Original Article Zur Zeit gratis

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

verfasst von: Shiv Kumar Sarin, Ashok Choudhury, George K. Lau, Ming-Hua Zheng, Dong Ji, Sherief Abd-Elsalam, Jaeseok Hwang, Xiaolong Qi, Ian Homer Cua, Jeong Ill Suh, Jun Gi Park, Opass Putcharoen, Apichat Kaewdech, Teerha Piratvisuth, Sombat Treeprasertsuk, Sooyoung Park, Salisa Wejnaruemarn, Diana A. Payawal, Oidov Baatarkhuu, Sang Hoon Ahn, Chang Dong Yeo, Uzziel Romar Alonzo, Tserendorj Chinbayar, Imelda M. Loho, Osamu Yokosuka, Wasim Jafri, Soeksiam Tan, Lau Ing Soo, Tawesak Tanwandee, Rino Gani, Lovkesh Anand, Eslam Saber Esmail, Mai Khalaf, Shahinul Alam, Chun-Yu Lin, Wan-Long Chuang, A. S. Soin, Hitendra K. Garg, Kemal Kalista, Badamnachin Batsukh, Hery Djagat Purnomo, Vijay Pal Dara, Pravin Rathi, Mamun Al Mahtab, Akash Shukla, Manoj K. Sharma, Masao Omata, APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640)

Erschienen in: Hepatology International | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis.

Methods

Data was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19.

Results

Altogether, 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR = 2.1 (1.1–3.7), p = 0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR = 8.1 (1.9–38.8), p = 0.002] predisposed more to liver injury than those without these. Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5 (11.6%)] or acute decompensation [4 (9%)]. Liver related complications increased (p < 0.05) with stage of liver disease; a Child-Turcotte Pugh score of 9 or more at presentation predicted high mortality [AUROC 0.94, HR = 19.2 (95 CI 2.3–163.3), p < 0.001, sensitivity 85.7% and specificity 94.4%). In decompensated cirrhotics, the liver injury was progressive in 57% patients, with 43% mortality. Rising bilirubin and AST/ALT ratio predicted mortality among cirrhosis patients.

Conclusions

SARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated. The CLD patients with diabetes and obesity are more vulnerable and should be closely monitored.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565–574CrossRefPubMedPubMedCentral Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565–574CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shaoshang Zazhi 2020;36:E005 Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shaoshang Zazhi 2020;36:E005
8.
Zurück zum Zitat Xie H, Zhao J, Lian N, et al. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int. 2020 (online ahead of print) Xie H, Zhao J, Lian N, et al. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int. 2020 (online ahead of print)
12.
Zurück zum Zitat Feng G, Zheng KI, Yan Q-Q, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020;8(1):18–24CrossRefPubMedPubMedCentral Feng G, Zheng KI, Yan Q-Q, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020;8(1):18–24CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020 (online ahead of print) D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020 (online ahead of print)
19.
Zurück zum Zitat Sarin SK, Choudhury A. Acute-on-chronic liver failure. Curr Gastroenterol Rep 2016;18(12):61 PMID: 27747458CrossRefPubMed Sarin SK, Choudhury A. Acute-on-chronic liver failure. Curr Gastroenterol Rep 2016;18(12):61 PMID: 27747458CrossRefPubMed
23.
Zurück zum Zitat Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev 2020;14:535–545CrossRef Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev 2020;14:535–545CrossRef
25.
Zurück zum Zitat Zhang Y, Zheng L, Liu L, et al. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan City, China. Liver Int. 2020 (online ahead of print) Zhang Y, Zheng L, Liu L, et al. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan City, China. Liver Int. 2020 (online ahead of print)
29.
Zurück zum Zitat Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017;66:1154–1164CrossRefPubMed Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017;66:1154–1164CrossRefPubMed
30.
Zurück zum Zitat Sarin SK, Choudhury A, Sharma MK, APASL ACLF Research Consortium (AARC) for APASL ACLF working Party, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int 2019;13(4):353–390CrossRefPubMed Sarin SK, Choudhury A, Sharma MK, APASL ACLF Research Consortium (AARC) for APASL ACLF working Party, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int 2019;13(4):353–390CrossRefPubMed
Metadaten
Titel
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
verfasst von
Shiv Kumar Sarin
Ashok Choudhury
George K. Lau
Ming-Hua Zheng
Dong Ji
Sherief Abd-Elsalam
Jaeseok Hwang
Xiaolong Qi
Ian Homer Cua
Jeong Ill Suh
Jun Gi Park
Opass Putcharoen
Apichat Kaewdech
Teerha Piratvisuth
Sombat Treeprasertsuk
Sooyoung Park
Salisa Wejnaruemarn
Diana A. Payawal
Oidov Baatarkhuu
Sang Hoon Ahn
Chang Dong Yeo
Uzziel Romar Alonzo
Tserendorj Chinbayar
Imelda M. Loho
Osamu Yokosuka
Wasim Jafri
Soeksiam Tan
Lau Ing Soo
Tawesak Tanwandee
Rino Gani
Lovkesh Anand
Eslam Saber Esmail
Mai Khalaf
Shahinul Alam
Chun-Yu Lin
Wan-Long Chuang
A. S. Soin
Hitendra K. Garg
Kemal Kalista
Badamnachin Batsukh
Hery Djagat Purnomo
Vijay Pal Dara
Pravin Rathi
Mamun Al Mahtab
Akash Shukla
Manoj K. Sharma
Masao Omata
APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640)
Publikationsdatum
04.07.2020
Verlag
Springer India
Schlagwort
COVID-19
Erschienen in
Hepatology International / Ausgabe 5/2020
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-020-10072-8

Weitere Artikel der Ausgabe 5/2020

Hepatology International 5/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.